Product Code: SR112025A4880
The global tissue engineering market size reached USD 20.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 51.0 Billion by 2033, exhibiting a growth rate (CAGR) of 10.9% during 2025-2033. The market is driven by the increasing demand for regenerative medicines and TE procedures, rising incidences of fatal road accidents and trauma injuries, the augmenting need for bone implants among patients, continual technological advancements in the field of three-dimensional (3D) tissue engineering, and rising healthcare expenditure.
Tissue engineering (TE) is a biomedical engineering discipline that combines cells, scaffolds, and biologically active molecules into functional tissues. It applies the principles of life sciences and engineering to develop biological substitutes to restore, improve, maintain, or replace different types of tissues or organs. It provides efficient alternatives to transplants, surgical reconstruction procedures, and other mechanical devices that are used to repair damaged tissues. As a result, tissue engineering is rapidly gaining traction in numerous medical applications, including burn treatment, neurology, wound care, orthopedic, musculoskeletal, cardiovascular, and urological products. Nowadays, researchers are focusing on developing biomaterials for skin substitution to meet the growing demand for relatively cheaper and easily available skin replacement products.
Tissue Engineering Market Trends:
Tissue engineering procedures have proven effective in treating irreversible damage to tissues. This has led to a significant increase in the demand for regenerative medicines and TE procedures, which represents the primary factor driving the market growth. Besides this, the rising incidences of fatal road accidents and trauma injuries, along with the growing need for bone implants among patients, are augmenting the product demand. Additionally, the widespread prevalence of chronic diseases, such as diabetes, cancer, obesity and cardiovascular disorders, due to sedentary lifestyle habits, aging population and unhealthy diets, is catalyzing the market growth. Furthermore, technological advancements in the field of three-dimensional (3D) tissue engineering, such as organ-on-a-chip technology, replacement of embryo cells with stem cells, and use of 3D bioprinters to design in vitro implants efficiently, are offering lucrative opportunities to the market. Moreover, several product innovations, and the increasing government funding and private investments in research and development (R&D) activities are propelling the market growth. Other factors, including the growing number of replacements and reconstructive surgeries, rising consumer healthcare expenditure, and surging demand for plastic surgeries, are also creating a positive market outlook.
Key Market Segmentation:
Breakup by Type:
- Synthetic Scaffold Material
- Biologically Derived Scaffold Material
- Others
Breakup by Application:
- Orthopedics and Musculoskeletal
- Neurology
- Cardiovascular
- Skin and Integumentary
- Dental
- Others
Breakup by End User:
- Hospitals and Clinics
- Ambulatory Facilities
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., B. Braun Melsungen AG, Baxter International Inc, Becton, Dickinson and Company, Integra LifeSciences Corporation, Organogenesis Holdings Inc, RTI Surgical, Smith & Nephew plc, Stryker Corporation, Vericel Corporation and Zimmer Biomet.
Key Questions Answered in This Report
- 1.What was the size of the global tissue engineering market in 2024?
- 2.What is the expected growth rate of the global tissue engineering market during 2025-2033?
- 3.What are the key factors driving the global tissue engineering market?
- 4.What has been the impact of COVID-19 on the global tissue engineering market?
- 5.What is the breakup of the global tissue engineering market based on the type?
- 6.What is the breakup of the global tissue engineering market based on the application?
- 7.What are the key regions in the global tissue engineering market?
- 8.Who are the key players/companies in the global tissue engineering market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Tissue Engineering Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Synthetic Scaffold Material
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Biologically Derived Scaffold Material
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Others
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
7 Market Breakup by Application
- 7.1 Orthopedics and Musculoskeletal
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Neurology
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Cardiovascular
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Skin and Integumentary
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Dental
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 7.6 Others
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
8 Market Breakup by End User
- 8.1 Hospitals and Clinics
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Ambulatory Facilities
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 AbbVie Inc.
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 B. Braun Melsungen AG
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 SWOT Analysis
- 14.3.3 Baxter International Inc
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Becton, Dickinson and Company
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 Integra LifeSciences Corporation
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 Organogenesis Holdings Inc
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.7 RTI Surgical
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.8 Smith & Nephew plc
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Stryker Corporation
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 Vericel Corporation
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
- 14.3.11 Zimmer Biomet
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.11.3 Financials
- 14.3.11.4 SWOT Analysis